Business
Wave Life Sciences Ltd.: our business, including our research and development activities, preclinical studies and clinical trials, supply of drug product, and workforce.
Revenue decreased 60.5% to $42.7M, while Net loss of $204.4M.
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $42.7MWatch
- Profitability — Net loss $204.4MWatch
- Cash generation — Free cash flow −$188.2MNote
- Insiders — 5 buys; 20 sells in 365 daysOK
- Capital — Comparable payout data unavailableNote
Where the revenue comes from
Fiscal 2024, as Wave Life Sciences Ltd. reports it. History and quarterly detail are in the app.
- Category One Programs$71.3M
Latest filings
- DEF 14A · Annual proxy (pay & governance)2026-10-14
- 8-K · Company announcement2026-07-30
- 10-Q · Quarterly report2026-07-30
- 8-K · Company announcement2026-06-26
- 8-K · Company announcement2026-05-18
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Wave Life Sciences Ltd., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.